ArticleAME case reports2026
Classical Hodgkin lymphoma as a second malignancy in a patient with cervical squamous cell carcinoma following chemoradiotherapy: a case report.
Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concurrent chemoradiotherapy is the established standard treatment for locally advanced cervical cancer. However, it may increase the risk of second primary malignancies in long-term survivors. In our study, we present a case of classical Hodgkin lymphoma (cHL) arising as a secondary neoplasm in a patient with cervical squamous cell carcinoma who was treated with definitive chemoradiotherapy. By presenting this case, we try to find the relation between chemoradiotherpy and cHL and we emphasize the key element to diagnose cHL. Case Description: The patient was a 65-year-old woman diagnosed with stage ⅢB cervical squamous cell carcinoma in 2020. She received three cycles of cisplatin-based chemotherapy combined with image-guided radiation therapy (IGRT). In August 2025, she presented with persistent fever, productive cough and systemic lymphadenopathy. Initial investigations confirmed severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2) infection and extensive lymph node enlargement on cross-sectional imaging. Despite clinical resolution of the SARS-CoV-2 infection and empirical antibiotic therapy, she continued to experience recurrent high-grade fever. Excisional biopsy of an intact enlarged right axillary lymph node was performed and pathological examination confirmed cHL. After positron emission tomography/computed tomography (PET/CT) examination, she was diagnosed as stage IVB cHL. After four cycles of tislelizumab combined with the pirarubicin, vinblastine, dacarbazine regimen, the patient achieved complete resolution of symptoms. Conclusions: Radiotherapy, cisplatin-based chemotherapy, Epstein-Barr virus (EBV) activation, age-related immunosenescence, poorly controlled long-term diabetes mellitus (DM) and SARS-CoV-2 infection-related immunosuppression may have collectively contributed to lymphomagenesis. This case highlights the critical need for sustained long-term follow-up in cervical cancer patients, especially those burdened with concurrent chronic diseases. In the setting of unexplained fever or lymphadenopathy, clinicians must differentiate secondary malignancies from primary tumor recurrence. During the pathological diagnostic process, examination of an intact lymph node is essential for diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.